Skip to content
Screener

Vistagen Therapeutics, Inc. VTGN Q2 2026 earnings

Reported August 14, 2026 · Before market open

Revenue$1.5MBeat by $976.0K
EPS-$0.30Beat by $0.07
Revenue estimate$500.0K
EPS estimate-$0.37

Next report

Nov 12, 2026 (in 2 months)
Revenue estimate$500.0K
EPS estimate-$0.37

FAQ

When did Vistagen Therapeutics, Inc. report Q2 2026 earnings?
Vistagen Therapeutics, Inc. (VTGN) reported Q2 2026 earnings on August 14, 2026 before market open.
What were Vistagen Therapeutics, Inc.'s Q2 2026 revenue and EPS?
Vistagen Therapeutics, Inc. reported revenue of $1.5M and eps of $-0.30 for Q2 2026.
Did Vistagen Therapeutics, Inc. beat estimates in Q2 2026?
Revenue beat the consensus estimate of $500.0K by $976.0K. EPS beat the consensus estimate of $-0.36 by $0.07.
How did Vistagen Therapeutics, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 504.9% from $244.0K a year earlier and eps grew 36.2% from $-0.47.
Where can I find Vistagen Therapeutics, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-056953) and the 10-Q periodic report (0001628280-26-057116) directly on SEC EDGAR. The filing index links above go to sec.gov.